Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact email@example.com
- Dr. Perakslis was previously Chief Information Officer and Chief Scientist at the FDA
- Previously Dr. Perakslis served as Executive Director of Harvard Medical School's Center for Biomedical Informatics, SVP at Johnson & Johnson, and most recently as SVP of Bioinformatics at Takeda.
SAN FRANCISCO, Jan. 3, 2018 /PRNewswire/ -- Datavant announced today the appointment of Dr. Eric Perakslis as Chief Scientific Officer. In this role, Dr. Perakslis will bring extensive bioinformatic knowledge and thought leadership to accelerate Datavant's mission of organizing and integrating the world's healthcare data.
One of the foremost leaders in healthcare data informatics, Dr. Perakslis brings decades of clinical trial, R&D, academic, technical, and policy experience to Datavant's leadership team:
"We are thrilled to welcome Dr. Eric Perakslis onto our leadership team," said Travis May, Co-Founder and President of Datavant. "Dr. Perakslis brings decades of experience at the edge of technology innovation in the pharmaceutical industry, a strong reputation as a thought leader, a keen intellect, and passion for improving patient outcomes. His leadership will be invaluable in reaching Datavant's ambitious goal of using data to double the percentage of drugs that succeed in late-stage clinical trials by 2020."
Datavant is a technology company dedicated to organizing and integrating the world's healthcare data. Based in San Francisco, Datavant's products improve the design and interpretation of clinical trials through data integration and artificial intelligence, increasing the odds of success of clinical trials and helping more drugs reach patients.
Datavant's vision is backed by Roivant Sciences, SoftBank Vision Fund, and Founders Fund.
©2017 PR Newswire. All Rights Reserved.